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ABSTRAcr 
This study developed a general model for the calculation of drug therapy costs for 
cost comparison of two or more therapeutically equivalent drugs. In order to identify all 
the costs of drug therapy, the drug use process ~as extensively studied and analyzed. A 
computer program was created to facilitate the calculations of drug therapy costs. Of 
importance, the study indicated that including only the acquisition cost of drug would 
provide values far below the actual costs, and that personnel costs can affect total drug 
costs substantially. Health care providers (phannacists, physicians, hospital administrators 
and nurses) should include not only the acquisition cost of the drug, but also all other costs 
in their calculation of drug therapy. 
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1 - INTRODUCTION 
Health care costs have risen from 4.4% of the gross national product in 1950 to 
10.6% in 1984 (1). Hospital expenditures in community hospitals alone rose from $14 per 
day in 1950 to $245 per day in 1980 (2). Because of the alanning rise in health-care costs, 
cost containment measures are crucial to hospital managers, physicians and pharmacists. 
With the implementation of diagnosis-related groups (ORO) in October 1983, cost 
containment in all aspects of hospital care has become necessary for hospitals to survive 
(3). 
Drugs have not been exempted from the effects of health care cost containment. 
Although drugs and pharmaceuticals contribute on the average only 5% of hospital 
expenses (4), secondary to personnel costs, they are the most visible category of health 
care costs. It is also important to consider that about 6 to 8% of hospital costs are 
attributable to drug therapy costs (5). 
One mechanism for containing drug costs is more rational, economical prescribing 
practices (6). However, the need for improved prescribing comes at a time when the 
selection of drugs has become difficult due to increasing numbers of agents. This is 
especially true for newer compounds such as the third-generation cephalosporins. In the 
literature, many examples exist where cheaper and older drugs can produce the same or 
even better results than the expensive newer ones (7,8,9,10,11). 
Drugs, especially antibiotics, have a documented history of irrational uses which 
has unnecessarily increased the cost of drug therapy (12,13,14,15,16,17). Several studies 
have shown that substantial savings can be achieved through more rational drug therapy 
without compromising the patient (7,9,10,11,14,18). 
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When two or more drugs are therapeutically equivalent ( considering that 
pharmaceutical considerations should not be ignored, such as palatability, dosage form and 
convenience), cost becomes the decisive factor in the choice of drug therapy. However, 
comparing only the acquisition costs of drugs will not serve the purpose well. All costs 
associated with drug therapy from the acquisition of a drug through to its administration to 
the patient and monitoring of the therapy should be included when comparing the costs of 
drugs. Before 1980 most researchers conducting cost comparisons of equivalent drug 
therapies considered only the acquisition cost of the drug when calculating the cost of drug 
therapy and did not include other costs (7,8,17,18,19,20). 
Statement of the problem and objectives of the study 
Statement of the problem 
If physicians and pharmacists were aware of all the costs involved in drug therapy, 
it still would be not feasible to expect them to calculate all the costs each time a decision 
concerning two therapeutically and pharmaceutically equivalent drugs was made. It is not 
easy to quickly identify the various costs involved in drug therapy because of the large 
variety. The calculation of drug therapy costs based on the acquisition cost of the drug 
will not furnish results that well represent total drug costs for comparison of two 
therapeutically equivalent drugs, though it seems the easiest and fastest way. From the 
drug use process, it is clear that the calculation of drug therapy costs involves a 
considerable number of calculations. Without a computerized software program it would 
certainly be discouraging to try to calculate total drug costs. Therefore, it is important that 
a generic computerized model, which includes all the costs for calculating drug therapies, 
be created to help health care providers (physicians and pharmacists) compare two or more 
therapeutically equivalent drug therapies. 
Objectives of the study 
The objectives of this study are to : 
1) Identify the relevant costs (in dollar value) of total drug therapy for selected 
drugs at the University of Utah Hospital. 
2) Create a general cost calculation model for the following phannaceutical 
fonnulations : oral, injectable, topical and ophthalmic medications. 
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3) Write a computer program of the general cost calculation model that can be used 
for all drugs to calculate their total drug therapy costs. 
4) Compare the difference between drug costs calculated from only the acquisition 
costs of the drug, to drug costs based on all costs calculated with the general cost 
calculation model. 
Literature review 
As early as 1972, researchers started to worry about the costs of drug therapy. 
Roberts and Visconti stated that irrational use of systemic antimicrobial drugs cost the 
patient, hospital and third party as much as $13,989.28 (76.8%) of the total annual 
$18,224.55 of antimicrobial drug costs (17) . However, they did not include the costs of 
preparation and administration in their calculations. It was mentioned that had this been 
done, higher costs for irrational and questionable therapy would have been found. Kunin 
et al. mentioned the high cost of antimicrobial drugs and made cost comparisons for 
several antimicrobials, but based the calculations on the acquisition costs only (6). 
In a general way, most of the studies concerning costs of drug therapy consider the 
cost per gram of the drug, either to convey the high acquisition cost of the drug or to 
compare costs among therapeutically similar drug therapies ( 8,10,18,19,20,) . This is 
especially true for antibiotics such as the cephalosporins and the aminoglycosides. For 
instance, McGowan and Finland considered only the acquisition cost of the drug by 
measuring the costs (increase or decrease) in grams of the antibiotics used per year when 
they evaluated the usage of antibiotics in a general hospital (18). The average amount of 
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ampicillin used was 7,127 g per year during 3 years (1966,1967,1968) when restricted; 
when not restricted, it raised to 57,60(} g the next year, 1969. From 1969 to 1972 a mean 
use of 62,613 grams per year was found. During 1971, more than $250,000.00 was spent 
on antimicrobial agents and this amount was calculated based only on the cost per gram of 
the antibiotics. 
The fITst mention of other costs besides acquisition costs was in 1976 when 
Klimek et ale compared the costs of two cephalosporins, cefazolin and cephalothin, 
considering the cost of administration (21). They concluded that the economic advantage 
of cefazolin was that it could be given intramuscularly, thus reducing costs involved with 
intravenous administration. Dudley and Barriere also mentioned that when doing cost 
comparisons among drugs one should consider dose frequency and route of administration 
(22). They determined that infrequent administration can often offset the greater 
acquisition cost of drugs with long serum half-lives. 
In their calculation of cost reduction for an antibiotic control program, Craig et al. 
found that the average quarterly cost for all the antimicrobials was $16,358.00 for 1972 
and that it could be reduced to $11,229.00 (31 % reduction) during the 18 months of the 
control program (13). For cephalosporins, the reduction in the quarterly costs (1972) was 
from $4,719.00 to $1,014 during the control program, and this accounted for 72% of the 
decrease in total costs for antimicrobial drugs. Again, cost and saving calculations were 
based on the acquisition costs of the antibiotics. Maki and Schuna, when studying 
antimicrobial misuse, concluded that the average cost of an appropriate course of therapy 
was $55.30 and $84.45 for inappropriate therapy. These results were calculated 
considering the potential for overdose. For 14,650 patients in 1975, the cost of 
unnecessary antibiotics was $70,465.00 . This amount was based on the acquisition cost 
of the drug (14). 
Noel and Paxinos reviewed cephalosporin use and performed a cost analysis. 
They studied the prescribing patterns for cephalosporin and restricted the use of 
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cephalothin in a university hospital (20). Cost savings were studied over a 3-year period . 
Cephalosporin costs were calculated utilizing the amount of cephalosporin used, the cost 
per gram, and the number of doses taken by the patient. The restriction of cephalosporin 
use and the substitution of cephalothin for cefazolin resulted in a projected savings of over 
$5,500.00 for the fiscal year 1976-1977. Katz and Schalamowitz also studied the 
restricted use of cephalosporins during a 9-month surveillance period (8). From a total of 
674 patients, they found that 92% received doses greater than those recommended in the 
literature. The dosage of cefazolin ranged from 1 gram every 4 hours to 1 gram every 6 
hours while in the literature the recommended dosage is 250 to 500 mg every 8 hour or 500 
mg to 1 gram for moderate to severe infections. Substantial savings were achieved with this 
program, a total of $33,196.00. The total amount of cephalosporin used decreased by 
29%. These savings were calculated based on the quantity purchased, in grams. 
When surveying cephalosporin use, Arthurson et aL calculated the cost of different 
courses of antibiotics and compared cephalosporin costs to penicillin costs (7). Drug costs 
were based only on invoice prices of the drugs. They found that the inappropriate use of 
cephalosporins would cost approximately $ 25.00 for the whole therapy, about twice that 
of more appropriate drugs. 
It is interesting to mention that although Scheife et al. calculated the cost of cefoxitin 
sodium and clindamycin phosphate plus amikacin sulfate based only on the acquisition cost 
of the drugs, they concluded that the total cost of drug therapy can be influenced by other 
factors as personnel and material costs, besides drug cost (23). They emphasized that 
when those factors are present, they must be considered in cost analysis. 
Paxinos et al. considered material and laoor costs in their study of contannnation 
rates and costs associated with the use of four intermittent intravenous infusion systems 
(24) . They concluded that the major factor affecting the differences in costs is material 
costs and that labor costs accounted for only a small percentage of the total cost of the 
system and did not change the rank order costs established by material costs. 
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Only after 1980 did more studies begin to include other costs in addition to the 
acquisition cost of the drug . However, studies comparing the costs of two or more drug 
therapies based only on acquisition costs of the drugs can still be found. The study of 
Jewesson et al. (19) as well as that of Hayman and Sbravati (25) are good examples of this 
method of analysis. When auditing the use of cefoxitin at a 1,OOO-bed major teaching 
hospital in Vancouver, Jewesson et al. found that the cefoxitin use increased from 17.7% 
($15,300.00) of the pharmacy's costs for cephalosporins during the frrst year of its 
availability to 47.7% ($60,707.00) during the second year. The cost was calculated by 
adding the total amount of cefoxitin used (in gram) multiplied by the cost per gram. In their 
calculations of cefoxitin costs, no other costs were considered. From Hayman and 
Sbravati's study of restricted use of cephalosporin and aminoglycoside during a 12 month-
study, it was found that second-generation cephalosporin use decreased 52.2% (from 
43,111 to 20,159 doses) with an increased use of 48.3% (35,319 to 52,414 doses) of first-
generation cephalosporins. Tobramycin use was decreased by 75.9% and there was a 
229% increase in gentamicin use. During the study period, the expenditure for injectable 
antibiotics was $193, 172.06 less than during the year immediately precedings the 
restrictions. With the program, a decrease of $1.09 per patient day occurred in the total 
antibiotic cost. The cost savings were calculated using both (the first and the second 
generation of cephalosporins), and acquisition costs of the drug, but if other costs had been 
included, savings would have been higher. 
When evaluating the use of antibiotic prophylaxis, Crossley and Gardner (1981) 
included the acquisition cost of the antibiotics, plus the cost of solutions and tubing in 
their estimation of antibiotics costs (12). According to Rapp et ale (1981), "the true cost of 
antibiotic therapy involves considerably more than the cost of the agent employed" (26) . 
They also mentioned that the costs ancillary to the antibiotic agent rarely have been studied. 
The ancillary costs they referred to were: 1) administration supplies; 2) laboratory 
monitoring; 3) phannacy preparation time; and 4) nursing administration time. Their 
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conclusions were that: a) the cost of the antimicrobial agent comprised only 50% of the 
total antibiotic therapy costs for single-agent therapy; b) 54% of total cost for combination 
therapy; and c) that ancillary services occupied a fixed portion of costs and were related to 
the number of doses of antimicrobial agents. 
Suzuki and Palham mentioned that studies about the cost-benefit of providing 
antimicrobial education and consultation failed to report the exact cost of providing 
education and consultation service and also the total material and personnel savings 
involved (27). For that reason, they detennined drug costs by including the costs of the 
preparation and administration of drug therapy. They believed that important variables 
such as intravenous materials and personnel time (technicians, nurses and phannacists) 
should be considered. The variables with injectable drugs were the acquisition costs of the 
drug, the diluent, the intravenous supplies, the intravenous piggyback seal and intravenous 
secondary set used by the nurse when administering the drug to the patient. They 
concluded that other costs should be present when calculating drug costs. Later, in his 
study comparing three different methods of preparing parenteral lidocaine solution for 
intravenous drip at Brigham and Woments hospital, Feldman detennined that the volume 
control set system was more expensive than the syringe method when the cost of needed 
materials was included (28). 
In comparing costs for reconstituted parenteral antibiotics, Tanner also included 
personnel and supply costs associated with preparation, dispensing and administration 
(29). Personnel costs were the costs associated with the pharmacist, the nurse and the 
technician. The supply costs that he considered relevant were: dextrose (5%, 50 ml), 
administration set, secondary set, syringe (10 ml), needle (18 gauge, 1.5 inch), swabs and 
sterile water (10 ml). He concluded ~at for maximization of cost containment, the route of 
administration should change from intravenous to intramuscular and that less frequent 
administration would provide cost savings. Cost savings would be due to decreased costs 
for drugs and supply changes, personnel time, inventory costs, waste problems, patient 
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risk and length of hospitalization. He detennined that the decreased number of 
administrations offrrst-generation and second-generation cephalosporins varies from 
$76.64 (25% reduction in doses administered) to $229.92 (75% reduction for the 
piggyback intravenous system and from $42.02 (25%) to $141.08 (75%) for the volume 
control intravenous set system. He also calculated the projected national cost savings for 
the first and second-generation cephalosporin based on the predicted antibiotic usage for 
1983 . Cost savings would be from $ 62.2 million (25% reduction in doses administered 
with adjustment for no conversion to intramuscular or intravenous push administration) to 
$267.7 million (75% reduction). 
Reilly et al. compared costs between two systems ( syringe pump system and 
piggyback bottle system) for intennittent intravenous administration of small-volume 
injections, by separating the costs of both systems into flXed costs (small-volume 
container, label, container safety seal and transfer needle) and variable costs (secondary set, 
primary infusion set, with valve, adult and primary infusion set, plain, adult) (30). 
Personnel and material costs were included. They concluded that there was no difference in 
personnel costs between the two systems, but variations in time were required for 
individual tasks and, that the change from piggyback bottle system to syringe pump system 
would reduce the costs due to the reduction in material acquisition costs. Gouveia also 
stated that in providing drugs to patients, one should consider all costs of dispensing, 
distribution and administration (5). 
Parr et al. did one of the best and most complete studies involving costs of drug 
therapy for injectable drugs (31). They calculated total costs for a therapeutic course 
including drug costs, supply costs and personnel costs for seven therapeutically equivalent 
intravenous antibiotic combinations for a simulated febrile neutropenic patient. A 
computerized model was developed including the various cost elements that contribute to 
the overall cost of preparing and administering those seven drugs. The laboratory costs for 
serum aminoglycoside blood concentration were also included. They concluded that the 
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total costs of antibiotics were directly proportional to the acquisition costs of drugs and 
materials and that material costs represent from 72 to 94% of the total cost of therapy. The 
cost of a drug accounted for the major part of material costs ranging from 64% to 92% of 
the total costs. Personnel costs did not substantially affect total costs accounting for 6 to 
30% of the total costs, and the percentage varied from drug to drug. The material costs, for 
instance, of gentamicin-ticarcillin was $654.08 (72%) and for monolactam-piperacillin was 
$2,393.16 (94%), while the personnel costs for the monolactam-piperaci1lin was $149.95 
(6%), but for gentamicin-ticarcillin and cephapirin was $339.81 (30%). A shortcoming of 
the study was that they only considered the direct costs, thereby missing the indirect costs 
related to drug therapy, such as inventory storage costs, administrative personnel costs, 
utility bills, equipment depreciation and general overhead cost. 
After mid-1980, other costs related to drug therapy were mentioned. First, it was 
Fant in his study of controversies and pitfalls in monitoring arninoglycoside therapy (32). 
He concluded that the total cost of drug therapy should include the cost of toxicity due to 
drug therapy (often very difficult to quantify) besides all costs of drug preparation, 
administration and laboratory monitoring. Second, Baniere mentioned about 
controversies in antimicrobial therapy (fonnulary decisions on third-generation 
cephalosporins) emphasized that other factors besides acquisition costs should be included 
in total costs of drug therapy (33,34). Baniere was one of the first to mention the need to 
include indirect costs. The factors he considered important and that contributed to the total 
economic impact of antimicrobial agents were: 1) acquisition costs; 2) preparation; 3) 
distribution; 4) administration; 5) control systems; 6) storage and inventory; 7) monitoring; 
and 8) use in ambulatory care (postdischarge ambulatory or home care) . Control systems, 
storage and inventory and use in ambulatory care were added to drug costs and these costs 
were classified as indirect costs. 
This study attempted to measure the costs related to drug therapy. 
2-METHODS 
The drug use process was extensively studied and analyzed to identify all the 
elements that could directly or indirectly contribute to drug costs. The factors considered 
relevant were classified as direct costs and indirect costs. The direct costs comprise supply 
costs, personnel costs and laboratory costs, while the indirect costs include all 
administrative costs such as utilities, office supplies, cleaning costs, storage, equipment 
depreciation and personnel indirectly related to drug therapy. 
To quantify, in dollar value, the relevant costs in the drug use process, equations 
for direct and indirect costs were derived. The fonnulas were general in order not to be 
specific for the University of Utah hospital which was the site of the study. 
The Director of Phannacy at the University of Utah Hospital evaluated the 
identified relevant costs and helped to devise fonnulas to calculate the costs of drug 
therapy. This way relevant costs in the drug use process would not be missed. 
There are four methods to calculate the acquisition cost of drugs: 1) FIFO; 2) LIFO; 
3) average cost; and 4) specific invoice price. LIFO, which means last in, frrst out, was 
used because it gives a more realistic price during inflationary periods. It is the last invoice 
price and would allow some loss recovery to counteract purchasing process problems. 
FIFO (frrst in, fIrst out) could not be applied to drugs in a general way because it is very 
hard to find which was the price paid for a specific lot of the drug used. And the average 
cost for a drug is calculated from the average of the latest price and the last price. This 
method was not used because it was considered unappropriate . Also it is important to 
remember that it may cost more or even less to buy a drug at a specific moment when drug 
costs are being calculated. Last, the specific invoice price is usually used only for 
merchandise of great dollar value per dosage unit 
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The cost for 24 hours of drug therapy was used to compare costs between drugs. 
First, the unit dose was used for the calculation of drug costs. The unit dose would be a 
tablet for oral drugs, a single dose in gram or milligram for injectable drugs and a single 
dose in drop or m1 for liquids and ophthalmic drugs. The cost of one unit dose of the drug 
was calculated with the help of the computer program (created especially for this purpose) 
adding all the costs related to one dose of the drug. The result was multiplied by the 
number of doses per 24 hours to obtain total drug costs for 24 hours. Though a formula to 
calculate drug costs considering length of therapy in days was created in the computer 
program for this study, it was not used due to variations in length of stay for different 
patients. 
The selection of the drugs for this study followed one or more of the following 
primary criteria: 1) invoice.price; 2) dosing intervals; 3) preparation and monitoring; 4) 
adverse reactions; 5) route of administration; 6) length of therapy; and 7) formulary drug 
versus nonformulary drug. Comparisons were made for drugs differing in these criteria in 
order to determine the contribution of each criterion to the cost of drug therapy. 
The head nurses of two different floors determined the materials used in drug 
administration and drug monitoring and served to document the laboratory tests ordered 
by the physician. Only the laboratory tests ordered specifically_due to the drug 
administration were included in the calculation of drug therapy costs. However, the 
laboratory tests ordered routinely by the physicians that had connections with the drugs 
selected for this study were not considered in the calculation of total drug costs. For 
chlorthiazide and hydrochlorthiazide, the laboratory test included in the calculation of total 
drug costs was potassium and for gentamicin, it was gentamicin blood serum concentration 
12 
The costs of the drugs, intravenous supplies and personnel were provided by the 
Director of Pharmacy and the Phannacy Buyer. Prices of material costs which were not 
available to pharmacy personnel were obtained from the Hospital Storeroom supervisor. 
The acquisition costs of all materials were from 1985 inventory. All personnel wages used 
in the calculations of drug costs were average wages and included fringe benefits, with the 
exception of the pharmacy intern who does not receive benefits. Because the tasks 
performed in providing drug therapy took less than an hour and the wages were calculated 
on an hourly basis, it was necessary to recalculate wages from an hour to a minute scale. 
The change was perfonned in processing sections, 1040, 1050, and 1060 of the computer 
program. 
All materials that could not be directly allocated to a unit dose and that would 
provide a dollar value too small to be included as relevant costs were considered as indirect 
costs. For instance, during the preparation of injectable drugs, sterile gloves and 
extension sets were also used, but the technician prepared several unit doses of different 
drugs with the same pair of gloves (the same situation happened with extension sets). It 
was difficult to estimate the percentage of the glove cost used and therefore allocate to each 
unit dose of the drug , and that is why it was classified as an indirect cost. 
The time personnel (technician, pharmacist and nurse) spent with the preparation, 
the administration, and the monitoring of injectable drugs were extracted from the study of 
Parr et al. study (31). The reasons for employing these data were: 1) the main objective 
of their study was to calculate total costs of drug therapy and so it was the objective of this 
study; 2) it is by far one of the best designed and most complete studies in drug cost 
calculations; and 3) it had a large number of observations of the time nurses, technicians, 
and pharmacists spent performing a task. The number of observations varied from 60 to 
100. 
In this study, it was considered that nurses were involved in drug administration 
and monitoring; therefore the ,time the nurse spent in drug preparation was considered 
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zero. The time the nurse spent in drug administration and monitoring was 5.25 minutes per 
dose for the injectable drug. The time the clinical pharmacist spent monitoring the 
injectable drug (16 minutes) was divided by number of doses per 24 hours because it was 
assumed that it took 16 minutes for drug monitoring daily (31) . For the calculations of 
total drug costs in this study, it was considered that the pharmacist was involved in drug 
preparation and drug monitoring and did not have any relationship with drug 
administration. 
The time personnel spent in the administration and the monitoring of oral and 
topical drugs was obtained from Locklear's study (35). Those data were used because: 1) 
the project was performed at the University of Utah Hospital; 2) it was determined the time 
nurses spend in administering oral and topical drug; and 3) it was a well conducted study. 
No data reflecting the time technicians spent on repackaging unit doses from a bulk 
container for oral drugs (tablets) were found in the literature. Therefore, a stopwatch 
method was used to collect data at the pharmacy of the University of Utah Hospital. The 
observation of packing the unit dose tablets by the technician started from the moment he 
checked the drugs that should be packed in unit dose and stopped after he labeled the 
drugs. The process of packing tablets in unit dose was observed for variable times ( from 1 
to 3 hours) for 10 days. 
All other costs reflected costs to the hospital and not to the patient, including 
laboratory costs. The laboratory costs were furnished by ARUP (Associated Regional and 
University Pathologists, Inc.), an independent clinical laboratory that performs all 
laboratory tests for the University of Utah Hospital. 
A computer program was created for the general model to facilitate and make faster 
the calculation of drug costs, to provide a more efficient and precise way to calculate costs 
related to drug therapy, and to furnish consistency ( so all the drug costs calculations would 
be performed the same way). Also, this program made the calculation of drug costs more 
available to physicians, pharmacists, nurses, health care providers and other lay people 
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interested in drug costs calculations. With the assistance of a computer programmer, the 
program was written in the Basic language. Basic was used because it was considered the 
best language for this type of calculation, and also for the possibility that Basic can be used 
in other computers. To validate the program function and its accuracy, costs of one of the 
selected drugs (cefoperazone) were calculated. using a calculator. The results furnished by 
the computer program were compared with the ones obtained from the calculator. The 
computer program was designed using the formulas devised to calculate the costs and was 
created to be as general as possible, so it could be used for all pharmaceutical formulations 
and by other hospitals. Mathematical rounding was done on the results of total drug costs 
in the computer program. 
The calculation of drug costs based only on the acquisition costs of the drug was 
done with the computer program for doses over a 24 hour period. The same process was 
performed with the calculation of total costs of drug therapy. The costs of the materials 
used in the administration of injectable drugs were calculated by taking the acquisition cost 
of the materials divided by the number of doses per 24 hours. If the material was used for 
48 hours, its acquisition cost was divided by the number of doses per 48 hours. The 
materials used were: 1) dextrose 5% 500 ml (24 hours); 2) intravenous set with injection 
sites ( 48 hours); and 3) Harvard microbore extension set (48 hours). For solutions that 
were used in drug preparation, the process was that if 10 ml of the injection solution was 
used in drug preparation, then the cost for only 10 ml was calculated. 
To calculate the cost difference for the 16 selected drugs, the cost of drugs ( based 
on the acquisition cost only) was subtracted from total drug costs calculated using the 
computer model. To obtain the percentage, the difference between total drug costs and 
acquisition costs of drug was divided by cost of drugs and multiplied by 100. Percentage 
was used because the great variation in the acquisition costs of the selected drugs would 
not allow comparison. 
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Limitations of the study 
When studying the costs of drug therapy, the first important factor to remember is 
that the patient may be taking more than one medication. This means that the nurse may be 
administering other drugs to the patient at the same time, besides the one being studied. If 
this happened, it would certainly affect the time the nurse spent administering the drug. 
For this project it was assumed that the patient took only one medication at the time of the 
drug administration which mayor may not be the case. 
Another factor limiting this study is assuming that the most frequently 
recommended daily dosage was the standard one. For instance, for chlorthiazide, the 
dosage was considered as 1 tablet per day, but it may have happened that the patient had 2 
tablets per day, or even had 1 tablet every 48 hours. When calculating the costs of drugs, it 
is essential to consider the number of doses per 24 hours. 
To facilitate calculations, the indirect costs of drugs were considered as a percentage 
of the total direct cost. The number used (22.70 %) and assigned by the accounting 
department to pharmacy reflected how indirect costs would affect the costs of the drug 
considering pharmacy as a department of the hospital. The number used in the calculation 
of total drug costs may be more or less than the actual number. Indirect costs such as 
telephone bills, utilities bills, cleaning supplies, office supplies, storage, inventory, 
equipment depreciation, intangible costs and personnel indirectly related to the drug 
therapy (as housekeepers) were allocated as an estimation. If one had tried to calculate the 
costs of each indirect cost it would have taken not only a very long time but the results 
would also be represented as very insignificant values. Therefore, the results would still 
be an estimation and less precise than the percentage used. Another aspect restricting the 
use of indirect costs as a percentage of direct costs is that indirect costs are proportional to 
the dollar value of direct cost If direct costs were high, indirect costs were high too. That 
is, if the acquisition cost of a drug was high, indirect cost would be high, even if most of 
the indirect costs were (or should be) constant regardless of direct costs. But this 
shortcoming could be compensated by considering the fact that the more expensive the 
acquisition cost of the drug , the less capital the hospital has to use in profitable 
investments. 
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One of the most important factors not introduced in the calculation of drug therapy 
is the cost of adverse reactions which are costly not only to the patient but also to the 
hospital. The patient may suffer undesirable side effects of the drug and take other 
medications to suppress adverse reactions of the drug. It is not unreasonable to assume 
that the patient may even have to be hospitalized for a longer period of time. The latter 
would be certainly costly to the patient and to the hospital. 
The estimation of costs of the adverse drug reactions is a not an easy task. Adverse 
reactions vary from patient to patient. Some patients may be much more sensitive to the 
side effects of a drug than others, and the costs would most likely be different for different 
patients. So, with one single drug there are different adverse reaction costs for different 
patients. Considering the number of drugs used in a hospital, years of study would be 
necessary just to get an estimation of costs of adverse reactions for all drugs. These may be 
the reasons why not many data about costs of adverse reactions were available in the 
literature. In a study performed by a pharmaceutical company (Hoescht), estimations of the 
costs of adverse reactions for different antibiotics were performed. These data were not 
used in this study because: 1) it was a study done for only some antibiotics; and 2) it was 
necessary to make extrapolations of the data as only antibiotics were included. 
Unfortunately, conclusive data about costs of adverse drug reactions cannot be found, even 
though they are often speculated about. 
Another factor limiting this study was the data used for injectable drugs . 
Most of the data on the time personnel (nurse, technician and pharmacist) spent perfonning 
an activity were extracted from a study that was not done at the University Hospital. 
These data came from a hospital located in another geographic area with different 
techniques to prepare, and to administer injectable drugs. The main reason for using the 
data was because the study was well done. 
17 
Another factor that should be mentioned is laboratory tests. According to the head 
nurse there were routine lalxlratory tests that physicians ordered for the patient which may 
or may not be related to the drug the patient was taking. Not including laboratory tests 
related to drug administration may have changed total drug costs and reduced the results in 
dollar value. If more laboratory costs were included, total drug costs would have been 
higher than the results obtained in this study . 
Last, it is essential to mention that the drugs used to test the computer model were 
not chosen at random, but selected out of convenience. This process was done because it 
was necessary to include injectable, oral, topical and ophthalmic drugs. 
3 - RESULTS 
The drug therapy process was studied and six major steps were derived from it. 
The fIrst step is the prescription for the drug which is generally the responsability of the 
physician. After being prescribed, the drug is purchased by the Pharmacy department, 
and this second step is called acquisition. Many times drugs are purchased in multiple 
dose, or must be prepared before being administered to the patient, so this third phase 
was denominated as preparation. The drug is prepared in the Pharmacy and then it must 
be delivered to the patient, so this step was named delivery. After being delivered, the 
drug will be administered to the patient by the nurse, and this step was considered as 
administration. Finally, after receiving the drug, the patient will be monitored. It is 
important to observe that not all drugs have to go through all these steps, and for some 
drugs, one or two steps mentioned above do not exist. Each step was analyzed to find 
the relevant factors contributing to the total costs of drug therapy. This study of the drug 
use process generated the following results: 
The prescription is the first phase of drug therapy and it provides the following 
infonnation: 1) number of doses per 24 hours; 2) route of administration; and 3) length 
of therapy. 
The acquisition is the second phase of drug therapy and consists of : 1) the 
acquisition cost of the drug ; 2) the wages of the buyer that are proportional to the time 
spent ordering the drug; 3) the wages of the receiving clerk that are proportional to the 
time the receiving clerk spends receiving the drug; 4) the wages of the storekeeper that are 
proportional to the time the storekeeper spends to put drug on the shelves; and 5) 
administrative costs. 
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Administrative costs included: 1) materials such as office supplies and cleaning 
supplies; 2) utility bills -- electricity, gas and water; 3) telephone bill, like long distance 
calls; 4) equipment depreciation, e.g., typing machine, xerox machine, computer; 5) 
administrative salaries, e.g., secretary, computer programmer, supelVisor, assistant 
director of pharmacy; 6) costs related to messengers; 7) department cost -- general 
overhead; 8) drug wastage due to drug preparation and expiration of the drug; and 9) 
taxes (this item was not included for the University Hospital because it is a nonprofit 
hospital ). Also, it is important to remember two constant costs : 1) drugs in stock 
which represent capital that could be in the bank gaining interest; and 2) inventory storage 
costs (the personnel required to perfonn the yearly inventory and the shelve space the 
drugs need, both costing money to the hospital). The department costs are all the costs 
that are indirectly related to drug therapy such as providing journals, sending pharmacists 
to conferences, meetings, hiring personnel (turnover), etc. These are indirect costs. The 
direct cost for acquisition cost phase is the invoice price for a unit dose of the drug. 
Drug preparation is the third phase of drug therapy . The factors included in this 
phase are: 
1) the cost associated with the pharmacist's wages per hour proportional to the 
time spent with drug preparation. 
2) the cost associated with the technician wages per hour proportional to the time 
spent in drug preparation. 
3) the cost associated with the nurse's wages per hour proportional to the time 
spent in drug administration. 
4) the materials used for drug preparation. 
5) the cost of the drug considering drug wastage during the preparation of a unit 
dose. 
6) the monthly depreciation of the equipment used in the preparation of the drug 
such as unit dose tablet packaging machines and laminar flow cabinets. 
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Drug delivery is the fourth phase of drug therapy. This step included the cost of the 
messenger ( messenger's wages) and the depreciation of the delivery cart if it is being 
used. But in emergency cases, only a few doses are delivered, so the delivery cart is not 
necessary. 
Drug administration is the fifth step of drug therapy and includes: 1) the personnel 
(nurse); 2) the materials; and 3) the depreciation of equipment. 
Drug monitoring is the sixth phase of drug therapy and is composed of: 1) the 
costs of the personnel monitoring the drug ( the nurse and/or the pharmacist); and 2) the 
cost of laboratory tests. 
To calculate the cost of drug therapy at the University of Utah Hospital, the 
following items were considered as the relevant costs: 1) the acquisition cost of the drug; 
2) the percentage of the drug lost during preparation of one unit dose of the drug; 3) the 
materials to prepare the drug; 4) the materials to administer the drug; 5) the materials to 
monitor the drug ; 6) the technician wages; 7) the time the technician spends on drug 
preparation; 8) the nurse's wages; 9) the time the nurse spends in drug preparation and 
drug administration; 10) the pharmacist wages; 11) the time the pharmacist spends on 
drug preparation and drug monitoring; 12) laboratory tests; and 13) indirect costs as a 
percentage of the total direct cost. 
The drug delivery phase was considered as indirect costs because: 1) many doses 
of different drugs were delivered and the number of the delivered doses varied 
considerably; and 2) the person who delivers drugs varied and could be anyone of the 
following group: nurse, technician or pharmacist. 
A general model for the calculation of the costs with formulas for the oral, 
injectable, topical and ophthalmic drugs was created. The calculation of drug costs was 
based on 24-hours of drug therapy and the elements considered were: 1) the cost for 
one dose of the drug; and 2) the number of doses per 24 hours. 
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The main fonnula ( number 1) needed to calculate the total drug costs consists of 
five separate equations and each equation will be described. The frrst equation is: 
Cd = COlD + CSID + CPID + CIID + CLID (1) 
where: 1) Cd is the cost for one dose of the drug 
2) COlD is acquisition cost of one dose of the drug 
3) CSID is the cost of supplies per dose 
4) CP ID is the cost of personnel per dose 
5) CIID is the indirect costs per dose 
6) CLID is the cost of the laboratory tests per dose. 
As mentioned before, when comparing the costs of two therapeutically equivalent 
drugs, it is better and easier to compare the cost of drug therapy for 24 hours than for 
the total length of the therapy, because the length of therapy may vary from patient to 
patient. Therefore, an equation was developed for this purpose. The equation for a 24 
hour drug therapy is : 
COd = Cd x Nd (2) 
where : 1) COd is the cost of a 24 hour drug therapy; 2) Cd is the cost of one dose of the 
drug; and 3) Nd is the number of doses per 24 hours. 
For cases where the costs of the whole length of drug therapy can vary from 1 to n, 
an equation was created: 
cr = COd x NDT (3) 
where: 1) cr is the total cost of the drug therapy; 2) NDT is the length of drug therapy; 
and 3) COd is as above (2). 
Each component of the equation (1) is described below. The first equation is for 
drug cost per dose (COlD), and is represented by : 
COlD = CPC1/NDC (4) 
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where: 1) CPC1 is the cost of the drug considering the amount of drug wasted in drug 
preparation; and 2) NDC is the number of doses in one container. The fonnula to include 
drug wastage is : 
CPC1 = CPC + WPR (5) 
where: 1) CPC is the acquisition cost of the drug without considering drug wastage, 
and 2) WPR is the percentage of the drug lost during the preparation of one dose of the 
drug. The equation for WPR is : 
WPR = X CPC (6) 
where: X is the percentage of the indirect cost 
When the drug is in the multiple dose container, the number of doses per container 
must be known. If there is only one dose in the container, then CD = CPC (where CD is 
the acquisition cost of the drug), and the dollar value would be the invoice price of the 
drug. 
The next equation is for the cost of supplies per dose (CSID) and is represented as : 
CSID = MPR + MAD + l\flv1:0 (7) 
where: 1) MPR is all the materials used for the preparation of a unit dose. To calculate it, 
all the costs of the materials used in drug preparation were added; 2) MAD is all the 
materials used for the administration of a unit dose. To calculate it, the same procedure 
was used for MPR; and 3) MMO is all the materials utilized in the administration of a 
unit dose. To calculate it, use the same procedure as for MPR . 
The equation CPID is the one that represents the cost of the personnel per dose. 
This equation involves technicians, nurses and pharmacists. Physicians are not included 
because patients must pay physician's fees separately. The equation for personnel costs 
is : 
CPID = cr + CN + CPH (8) 
where: 
1) cr is the cost associated with the technician, and its equation is : 
cr = STe x (tPRTe) (9) 
where: 
1) STe is the technician wages/hour; and 2) tPRTe is the time the technician spent on 
drug preparation. 
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2) CN is the cost associated with the nurse. The nurse can be involved in the preparation, 
administration and monitoring of the drug. The equation for CN is : 
CN = SN x (tPRN + tADN + tMN) (10) 
where: 1) SN is the nurse wages/hour ; 2) tPRN is the time the nurse spent in drug 
preparation; 3) tADN is the time the nurse spent in drug administration and; 4) tMN is 
the time the nurse spent in drug monitoring. 
3) CPH is the cost associated with the pharmacist, which can be involved in drug 
preparation, drug administration and drug monitoring. CPH's equation is : 
CPH = SPH x (tPRPH + tADPH + tMPH) (11) 
where: 1) SPH is the pharmacist wages per hour; 2) tPRPH is the time the pharmacist 
spent on drug preparation; 3) tADPH is the time the pharmacist spent on drug 
administration; and 4) tMPH is the time the pharmacist spent on drug monitoring. 
The equation that represents all indirect costs and intangible costs per dose of drug 
is the equation number 12 . These costs are the department's general overhead costs, 
costs associated with the buyer, store keeper, receiving clerk, and other personnel 
indirectly involved with the drug acquisition phase (housekeeping and maintenance 
personnel, administration personnel) drug wastage due to expiration, utility bills, 
equipment depreciation (all the equipment related directly or indirectly to the drug 
therapy), inventory costs, administrative personnel wages, messenger, etc. It is difficult 
to name all indirect costs, especially intangible costs. For the pharmacy as a department 
of the University hospital the formula that represents the allocation of these indirect costs 
is : 
CI = X DC (12) 
where: 1) CI is the indirect cost; 2) X is the percentage assigned by accounting 
department to pharmacy; and 3) DC is the direct costs. 
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The last equation represents the cost of laooratory tests per dose (CLIO) . The 
number of the tests performed during the therapy were added and divided by either the 
number of doses or days depending on what was needed: the total cost of the drug per 
dose or the drug cost per day. This step was necessary because laboratory tests are 
performed on a daily basis and only a single test may be required for the entire therapy. 
The equation for the cost of laooratory tests per day is : 
CL = Ltl + Lt2 + Lt3 + ...... (13) 
where Lt1, Lt2, Lt3 are the prices of different types of laboratory tests. If a test was 
performed more than once a day, the following equation was used: 
Lt(n) = It x NIt (n varies from 0 to infmite) (14) 
where: 1) It is the price of one laooratory test, and 2) NIt is the number of the laboratory 
tests in 24 hours. 
To test the software, eight pairs of drugs were selected from oral, injectable and 
topical drugs. The frrst set of drugs was gentamicin 80 mg and cefoperazone 1.0 gram. 
The criteria used to select these drugs were: 1) invoice price; 2) dosing intervals; 3) 
preparation; 4) monitoring; and 5) adverse reactions (especially for gentamicin). 
The second set of drugs was Actifed®a and Drixoral®b . This pair was selected 
because: 1) they are prescribed for cold symptoms; 2) they are oral drugs (tablets) ; 3) 
they have different invoice prices; 4) they have different dosing intervals; and 5) 
Drixoral® needs to be packed in unit dose, while Actifed® comes prepacked in unit dose. 
The main criterion utilized to choose the third set of drugs, gentamicin ophthalmic 
ointment and gentamicin solution ophthalmic, was the need to have a pair of topical 
a Actifed is tripoli dine hydrochloride 2.5 mg and pseudoephedrine hydrochloride 60 mg , 
and it is manufactured by Burroughs Wellcome Co. 
bDrixoral is dextropheniramine maleate and pseudoephedrine sulfate, and is manufactured 
by Schering Corporation. 
drugs. Their different ways of administration and different dosing intervals were also 
considered. 
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Ampicillin 500 mg capsules and ampicillin 1.0 gram intravenous was the fourth set 
of drugs selected. The main reason for choosing this set was to compare different 
dosage forms of ampicillin. Different preparation and invoice prices were other factors 
taken into account. 
The fIfth set of drugs was cimetidine 300 mg and ranitidine 150 mg. The criteria to 
select this pair were: 1) both are oral drugs; 2) both are prescribed for gastric ulcer; 3) 
they have different invoice prices; 4) they have different dosing intervals; and 5) they 
have different lengths of therapy. 
Darvocet-N 100®c versus propoxyphene hydrochloride 65 mg plus acetaminophen 
1.0 gram was selected as the sixth pair of drugs. The main reason for choosing these 
drugs was to compare the costs of formulary drugs to the costs of nonformulary drugs. 
The same criteria were utilized for the seventh pair of drugs, chlorthiazide 500 mg and 
hydrochlorthiazide 50 mg. 
The last pair of drugs was leucovorin calcium 25 mg versus folinic acid 25 mg . 
The main criterion for their selection was to compare costs of drugs prepared in the 
hospital pharmacy and drug product purchased from the manufacturer and or wholesaler. 
The materials used in the preparation of injectable drugs were alcohol swabs, 
solutions of dextrose 5% 500 mI, solutions of dextrose 5% 1000 mI, labels for the 
syringe, transfer needles, solutions of sodium chloride 0.45% 1000 mI, solutions of 
sterile water 500 ml and both 10 m1 and 60 mI-syringes and syringe caps. 
The available data to test the general computerized model for the calculation of drug 
costs were: 
1. The acquisition cost of the drugs is shown in Table 1. 
CDarvocet N-1 00 ® is propoxyphene napsylate and acetaminophen, and it is manufactured 
by Eli Lilly and Company. 
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Table 1 - Acquisition cost per container of the 16 selected drugs 
Drug Cost 
_ Acetaminophen 1 g 5000 tablets @ $ 28.99 
Actifed® 1000 tablets @ $ 14.59 
Ampicillin 500mg 500 tablet @ $ 35.50 
Ampicillin 1 g 1 g @ $ 0.65 
Cefoperazone 2g @ $ 18.40 
Cimetidine 300mg 100 tablets @ $ 32.49 
Chlorthiazide 500mg 100 tablets @ $ 9.57 
Darvocet N-1 oo® 500 tablets @ $ 47.15 
Drixora1® 100 tablets @ $ 18.49 
Folinic acid 25mg 1 capsule @ $ 4.05 
Gentamicin injectable 800mgJ20ml @ $ 1.65 
Gentamicin ophth. sol. 1 bottle 1 % 5ml @ $ 0.92 
Gentamicin ophth. oint. 1 tube 3 g @ $ 1.54 
Hydrochlorthiazide 5mg 1000 tablets @ $ 3.99 
Leucovorin 25mg 25 tablets @ $599.17 
Propoxyphene 65mg 500 tablets @ $ 38.60 
Ranitidine 150mg 60 tablets @ $ 40.33 
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2. The percentage of drug wastage was considered zero for oral and intravenous 
drugs. 
3. The acquisition costs of the supplies are shown in Table 2 . 
4. The preparation time, administration time and monitoring time spent by 
personnel for injectable, oral and topical drugs and the wages of the personnel are 
displayed in Table 3. 
5. The indirect costs for the pharmacy department (the percentage of X, see 
fonnula 12) at the University of Utah Hospital were considered as 22.70 % of the total 
direct costs ( with the exception of laboratory tests). The original number assigned was 
20.7%, but for the unidentified costs another 2% was assigned by the Director of 
Pharmacy. 
6. The prices of the laboratory tests are in Table 4. 
7. Table 5 shows the drugs with their route of administration and doses per 24 
hours. 
8. The cost of drug therapy was calculated based on the acquisition cost of the drug 
only and on all other relevant costs. The results are shown in Table 6. The differences 
between costs calculated from the purchase price and the cost calculated from all costs 
for the eight sets of drugs were compared. 
28 
Table 2 - Cost of the supplies used in drug therapy 
Supplies Unit Cost 
Alcohol swab $ 0.0175 
Plastic cup for tablets $ 0.0080 
Dextrose 5% 500ml $ 0.6500 
Dextrose 5% 1000ml $ 0.8300 
Harvard microbore extension set $ 3.3730 
IV set 2 injection sites $ 0.6920 
Label for syringe $ 0.0060 
Transfer needle $ 0.0400 
Sodium chloride 0.45% 1000ml $ 0.8500 
Sterile water 500ml $ 0.7700 
Sterilized syringe 10ml $ 0.3700 
Sterilized syringe 60ml $ 0.5500 
Syringe cap $ 0.0500 
Table 3 - Personnel time (in minutes) and wages per hour 
Personnel Time Time Time Salary 
(inj.) (oral) (topical) 
Phannacist 0.91 $ 17.80 
Ph arm. monit. 16.00 $ 17.80 
Nurse 5.25 1.03 1.33 $ 14.08 
Technician 3.16 0.29 $ 8.19 
Table 4 - Costs of laboratory tests 
Laboratory test 
Potassium 






Table 5 - The 16 selected drugs, their route of administration and number of doses per 24 
hours 
Drug Administration Dose p/24 hours 
Route 
Actifed® oral 4 
Ampicillin 500mg oral 4 
Ampicillin 1 g N 4 
Cefoperazone 1 g N 2 
Cimetidine 300mg oral 4 
Chlorthiazide 500mg oral 1 
Darvocet N-1 OO® oral 6 
Drixora1® oral 2 
Folinic Acid 25mg oral 4 
Gentamicin 80mg N 3 
Gentamicin oph.sol. a topical 4 
Gentamicin oph.oint. a topical 2 
Hydrochlorthiazidec oral 1 
Leucovorin 25mg oral 4 
Propoxyphene b oral 6 
Ranitidine 150mg oral 2 
a) administration of the drug to one eye only. 
b) propoxyphene + acetaminophen 1 g 
Table 6 - Difference between the calculation of the cost of drug therapy based on 
acquisition costs and the calculation of costs based on all costs for 24 hours 
Drug Actual inventory Calculated Cost difference 
cost cost 
Actifed® $ 0.06 $ 2.59 $ 2.53 (4217%)a 
Ampicillin 500mg $ 0.28 $ 1.57 $ 1.29 (461 %) 
Ampicillin 1 g $ 2.60 $ 25.91 $ 23.31 (897%) 
Cefoperazone 1 g $ 18.40 $ 37.80 $ 19.40 (105%) 
Cimetidine 300mg $ 1.30 $ 2.82 $ 1.52 (117%) 
Chlorthiazide 500mg $ 0.10 $ 1.14 $ 1.04 (1,040%) 
Darvocet N-1 OO® $ 0.57 $ 2.53 $ 1.96 (344%) 
Drixora1® $ 0.38 $ 1.19 $ 0.81 (213%) 
Folinic Acid 25mg $ 16.20 $ 21.10 $ 4.90 (30%) 
Gentamicin 80mg $ 0.49 $ 21.91 $ 21.42 (4,371 %) 
Gentamicin oph.sol. b $ 0.04 $ 1.58 $ 1.54 (3,850%) 
Gentamicin oph.oint. b $ 0.31 $ 1.14 $ 0.83 (268%) 
Hydrochlorthiazide $ 0.004 $ 1.03 $ 1.026 (26,650%) 
Leucovorin 25mg $ 95.87 $118.85 $ 22.98 (24%) 
Propoxyphene c $ 0.50 $ 2.45 $ 1.95 (390%) 
Ranitidine 150mg $ 1.34 $ 2.26 $ 0.92 (69%) 
a) cost difference was also calculated in percentage due to different acquisition costs of 
drugs 
b) administration of the drug to one eye only 
c) propoxyphene + acetaminophen 1 g 
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9. The costs of the personnel. materials. laboratory and indirect costs were 
calculated for all drugs, and the results are shown on Table 7. 
The computer program to calculate the cost of drug therapy was written in the 
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Basic language and was based on the 14 formulas described above. This program has three 
sections: the input section, the processing section and the output section. The input 
section gathers data. The processing section calculates material costs. personnel costs and 
laboratory costs. Finally, the output section gives the results. The software calculates the 
cost of drug therapy as the cost per dose, the cost per 24 hours and the cost per therapy. 
It also gives the percentage of: 1) material costs versus total costs; 2) personnel costs 
versus total costs; and 3) drug costs versus material costs. The program will answer 
questions such as the contribution of personnel costs and material costs (in percentage). 
The program is shown in its full details in the Appendix . 
Table 7 - Personnel costs, material costs (including drug costs) and indirect costs 
related to total costs in percentage 
Drug Material costs! Personnel costsl Indirect costs! 
Total Costs Total Costs Total Costs 
Actifed® 7.08% 74.53% 18.39% 
Ampicillin 500mg 19.87% 61.42% 18.71 % 
Ampicillin 1 g 33.33% 48.17% 18.50% 
Cefoperazone 1 g 58.72% 22.79% 18.49% 
Cimetidine 300mg 47.23% 34.28% 18.49% 
Chlorthiazide 500mg 9.10% 21.24% 69.66% 
Darvocet-N100® 24.43% 57.26% 18.31 % 
Drixoral® 34.29% 47.38% 18.33% 
Folinic Acid 25mg 76.93% 4.58% 18.49% 
Gentamicin 80mg 22.19% 48.13% 29.68% 
Gentamicin oph.sol. 2.53% 74.17% 23.30% 
Gentamicin oph.oint 27.19% 54.51% 18.30% 
Hydrochlonhiazide 1.16% 23.57% 75.27% 
Leucovorin 25mg 80.69% 0.81% 18.50% 
Propoxyphenea 23.84% 59.17% 16.99% 
Ranitidine 150mg 60.00% 21.37% 18.63% 
a) propoxyphene and acetaminophen 1 g 
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4 - DISCUSSION 
The computer program is open to changes either by deleting fonnulas or by adding 
equations, if necessary. Some people may argue that the created fonnulas and the 
computer program were too general, but it was designed this way to permit flexibility and 
let other hospitals besides the University hospital use them. This program calculates the 
costs of drug therapy in a simple and accessible way, and can be easily implanted in 
personal computers. It also allows anyone interested in drug therapy costs to calculate them 
provided that data (material costs, personnel costs and laboratory costs) are available. 
For Actifed® and Drixoral®, interesting results were found. If drug costs were 
based on acquisition costs only, Actifed® ($0.06) was six times cheaper than Drixoral® 
($0.38). But when all other costs were included. Drixoral® costs ($ 1.19) were half of 
Actifed's® ($2.59). These results were explained by the difference between Actifed's® 
dosage (4 doses per 24 hours) and Drixoral®'s dosage (2 doses per 24 hours). Drixoral® 
costs more than Actifed® and this was shown by higher percentage of material costs/total 
costs, for Actifed 's® percentage of material costsltotal costs was 7.08% while DrixoraI® 
had a ratio of 34.29%. 
Before discussing personnel costs related to drug therapy costs, it is essential to 
emphasize that personnel costs are fixed costs and not variable costs. For example, a 
nurse receives a fixed salary per year. However, the time spent on the administration of the 
drug to the patient varies with the number of doses and the fonn (oral, topical or injectable 
drug) of the medication. For instance, the nurse usually spends more time with an 
injectable drug than with an oral drug. However, the percentage of personnel costs in 
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relation to total drug therapy costs varies according to the acquisition cost of the drug, the 
supplies and laboratory costs. 
On the calculation of drug therapy costs. when considering the acquisition costs of 
cimetidine and ranitidine only, cimetidine 300 mg ($1.30 per day) was cheaper than 
ranitidine 150 mg ($1.34 see Table 1.6) . Nevertheless, when all other costs were 
included, cimetidine was more expensive ( $ 2.82 per day) than ranitidine ($2.26 per day). 
Material costs/total costs for cimetidine were lower ( 47.23%) than for ranitidine 
(60.00%). But the percentage of personnel costs/total costs were higher for cimetidine 
(34.28%) than for ranitidine (21. 37%). These results can be explained by the higher 
number of doses per day of cimetidine (4 per 24 hours for cimetidine versus 2 times a day 
for ranitidine) which increases the personnel and material costs. 
The number of doses per 24 hours for ampicillin 500 mg (oral) and ampicillin 1.0 g 
(injectable intravenous) was the same ( 4 per 24 hours). However, drug costs were quite 
different. For drug costs based on the acquisition costs only, ampicillin 500 mg ( $0.28) 
was nine times cheaper than ampicillin 1.0 g ($2.60). With all costs included, the 
difference was enhanced, for ampicillin 500 mg ($1.57) was 16 times cheaper than 
ampicillin 1.0 gram ($25.91). Since ampicillin 1.0 gram was administered intravenously, 
this medication required more material and personnel time for its preparation and 
administration. These differences were clearly shown on the percentage of material 
costs/total costs and personnel costs/material costs .. For ampicillin 1.0 gram, the ratio 
material costs/total costs was 33.33% and for ampicillin 500 mg was 19.87%. Due to the 
lower acquisition costs of ampicillin 500 mg , the percentage of personnel costs/total costs 
was higher for ampicillin 500 mg (61.42%) than for ampicillin 1.0 gram (48.17%), though 
the actual personnel costs were higher for ampicillin 1.0 gram (the nurse and the pharmacist 
spent more time with the patient). 
Hydrochlorthiazide was the least expensive drug among the 16 selected drugs. An 
immense difference, 132.650%, between the costs calculated on the acquisition costs of the 
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drug only ($0,004) and the costs based on all other costs ($5.31) was found, This enormous 
difference was mainly caused by laboratory costs of potassium test which accounted for 
94,16% of total costs. Due to the low acquisition cost of hydrochlorthiazide, the cost of the 
potassium test seemed extremely high ($ 5.(0) when compared to hydrochlorthiazide 
acquisition costs ($0.004). The same argument is true for chlorthiazide. the laboratory test 
accounted for 92.25% of the total costs. The high cost of laboratory tests suppressed by far 
material costs and personnel costs and this is true for both drugs. For chlorthiazide the 
material costs/total costs ratio was 1.99% and for hydrochlorthiazide was 0.24% . The 
personnel costs/total costs ratio for both drugs is also very low. For chlorthiazide it was 
4.46% and for hydrochlorthiazide 4.55%. From this set of drugs, it is possible to assume that 
laboratory costs can change drastically the ratio of material costs per total costs and the ratio of 
personnel costs per total costs. especially when the acquisition costs of the drug are very 
cheap. 
With laboratory tests present for gentamicin 80 mg. the ratio of laboratory cost/total 
costs is 29.68%. for chlorthiazide is 93.55%, and for hydrochlorthiazide is 95.21 %. then 
other costs (indirect costs plus laboratory costs) were higher than if these tests were absent. 
When the material costs ratio was low (chlorthiazide 1.99% and hydrochlorthiazide 
0.24%), and laboratory costs were much higher than the acquisition cost of the drug, then 
other costs accounted for the largest part of total costs. For all other drugs that did not 
include laboratory tests, other costs varied from 16.99% to 23.30%. 
From this study. it is clear that as the number of doses of a drug per 24 hours 
increases, material costs, personnel costs, and total drug costs also increase. A common 
widely used argument is that it does not matter the number of doses administered by nurses 
to the patient per day, because they are paid to work for fixed hours and they are in the 
hospital. However, it is worth remembering that saving nursing time in drug 
administration, the saved time can be used to perform other tasks (new programs) and also 
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that nurses will be able to give patients better care and have more patients to care without 
changing the quality of service (this will increase productivity). 
From Table 6, it is possible to infer that the difference among the drug costs 
calculated based on the acquisition cost only and the drug costs on all costs was quite 
significant. This difference varied from 24% to 132,650%. When the acquisition cost of an 
oral drug is high, the difference is not so tremendous (24%) as in the case of leucovorin 25 
mg ($ 95.85 per 24 hours). But if the acquisition cost of the drug is very low as for 
hydrochlorthiazide 50 mg ($ 0.004 per 24 hours), the difference is huge (132,650%). For 
Pharmacy and Therapeutics Committees, physicians and other health care providers when 
they have to make a decision between drugs and when cost is the main factor in their 
selection of two or more therapeutically similar drugs, it is essential to bear in mind that 
besides the acquisition cost of the drug, all other costs should be included in the 
calculation of drug therapy costs. 
Oral drugs seemed to present higher percentage of personnel costs per total costs. 
It was very interesting to observe that cheaper acquisition costs of a drug can produce 
higher personnel costs/total costs ratio. But one must remember that percentage is being 
discussed here and that personnel costs are fixed costs. When the rate of material costs per 
total costs was high, personnel costs/total costs rate was low. Several studies emphasized 
that personnel costs do not account heavily on drug costs (24,30, 31). For instance, 
Paxinos et ale concluded that personnel costs do not change the rank cost order established 
by material costs (24) and Reilly et ale determined that there was no difference in 
personnel costs when they compared piggyback bottle system and syringe pump system 
(30). Parr et ale also found that personnel costs do not affect total costs substantially, 
accounting from 6 to 30 % of the total costs (31). But, it is fundamental to mention that in 
those studies the drugs studied were presented in the injectable fonn, and that a great 
portion of the drugs were the ones considered expensive. This project included all 
phannaceutical formulations, inexpensive drugs and expensive drugs and these could be 
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the reason of the great variance in personnel costs (0.81 % to 74.53%). For personnel 
costs, Actifed® had higher personnel costs/total costs ratio (74.53%) than Drixora1® due to 
the higher number of doses per 24 hours, while Drixora1® had a lower number, two doses 
compared to four doses of Actifed® (47.38%). So for Actifed®, personnel costs/total 
costs were 74.53%, accounting for the majority of total costs. It was noticeable that for all 
selected drugs when material costs/total costs ratio was higher for one drug than for the 
other, personnel costs/total costs were lower for the drug with higher material costs. For 
the gentamicin ophthalmic solution, material cost was 2.53% and for the gentamicin 
ophthalmic ointment it was 27.19%. However, personnel cost for gentamicin Ophthalmic 
solution was 74.17% whereas it was 54.51 % for gentamicin ophthalmic ointment. The 
results of above mentioned studies (24,30,31) concluded that personnel costs do not 
account heavily on total costs as said previously, but this study found that personnel costs 
can account for the majority of drug therapy costs (up to 74.53%). The cheaper the 
material costs, the higher the personnel costs, and this relationship was valid for two 
therapeutically similar drugs when laboratory costs were not included in the costs of one of 
the drugs. 
5 - CONCLUSION AND FURTHER RESEARCH 
This study indicates that to calculate the costs of drug therapy based on the 
acquisition cost would provide values far below the actual costs. Health care providers, 
physicians, phannacists, and other people interested in drug costs should be aware that 
besides the acquisition cost of the drug, other costs should be included in the calculation of 
drug therapy costs. Realizing that there is a low probability of including all costs in the 
calculation of drug therapy costs, it is essential to include as many costs as can be identified 
and keep in mind that the obtained results may still not reflect the actual total. 
If it had been possible to include the costs of adverse reactions to the calculation of 
drug therapy, bigger differences between the cost of drug therapy based on acquisition 
costs and based on all costs would have been found in some cases. As mentioned before, 
adverse reactions have not been studied. There is a long way to go, as it will be necessary 
to find the best way to quantify and calculate adverse reactions costs for different drugs 
considering individual patient variations. This is an area that certainly deserves more 
attention and studies. 
APPENDIX 
COMPUTER PROGRAM 
100 REM INPUT SECflON 
103 INPUT "How many days will the therapy last?",NT 
106 INPUT "How many doses will be given per day?,NDPD 
110 INPUT "What is the price of the drug (invoice price)?'"CPC 
120 INPUT "How may doses are in one container?",ND 
125 WPR =0 
130 IF ND = 1 GOTO 150 
140 INPUT "How many different materials are used in preparing the drug?" , N 
160MPR =0 
170 IF N = 0 GOTO 230 
180FORI= 1 TON 
190 PRINT "What is the price per dose for material number ";1; If?" 
200INPUTMN 
210 MPR = MPR + MN 
220 NEXT I 
230 INPUT "How many different materials are used in administering the drug? ,N 
240 MAD =0 
250 IF N = 0 GOTO 310 
260FORI= 1 TON 
270 PRINT "What is the price per dose for material number If ;1; "?" 
280 INPUT MN 
290 MAD = MAD +.MN 
300 NEXT I 
310 IF MMO = 0 GOTO 390 
340FORI= 1 TON 
350 PRINT "What is the price per dose for material number" ;1; U?" 
360INPUTMN 
370 MMO = MMO +.MN 
380 NEXT I 
390 INPUT "What is the technician hourly wage?" ,ST 
400 INPUT "How many minutes does the technician spend on drug preparation?, TIP 
410 INPUT "How many minutes does the technician spend on drug monitoring?",TIM 
420 INPUT "What is the nurse hourly wages?",SN 
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430 INPUT "How many minutes does the nurse spend in administering the drug?",TNA 
440 INPUT "How many minutes does the nurse spend on drug monitoring?" ,TNM 
450 INPUT "What is the pharmacist hourly wage?",SP 
460 INPUT "How many minutes does the pharmacist spend on drug preparation?",TPP 
470 INPUT "How many minutes does the pharmacist spend in administering the 
drug?",TPA 
480 INPUT "How many minutes does the pharmacist spend on drug monitoring?",TPM 
490 INPUT "How many different laboratory tests will be done during the therapy?",N 
500CL=0 
510 IF N = 0 GOTO 570 
520 FOR I = 1 TO N 
530 PRINT 'What is the cost of lab test number";I;?" 
540 INPUT CLN 
545 INPUT "How many times will the test be done during the therapy?",M 
550 CL = CL + CLN * M 
560 NEXT I 
570 INPUT "What is the indirect cost as a percentage of the total direct cost?", CIP 
1000 REM PROCESSING SECllON 
1010 CPC1 = CPC * (1 + WPR/100) 
1020 CD = CPC1/ND 
1030 CS = MPR + MAD + MMO 
1032 TCS = CS * NDPD 
1034 TICS = TCS * NT 
1036 CM = CD + CS 
1039 TCM = CM * NDPD 
1040 CT = ST * (TIP + TIM) /60 
1050 CN = SN * (TNA + TNM) /60 
1060 CPH = SP * (TPP + TPA + TPM) /60 
1070 CP = CT+ CN +CPH 
1072 TCP = CP * NDPD 
1074 TICP = TCP * NT 
1080 REM COMPUTE THE TOTAL COST 
1090TC = (CD + CS + CP) * NDPD * NT 
1100 TC = TC * (1 + CIP/lOO) + CL 
1110 CPD = TC/NT 
1112 WTCP= TCP/CPD * 100 
1120 CPDS = CPD/NDPD 
1130 TC = INT(TC * 100 + .5) / 100 
1140 CPD = INT(CPD * 100 + .5) /100 
1150 CPDS = INT(CPDS * 100 + .5) /100 
1160 CL = INT(CL * 100 + .5) 
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2(x)() REM OUTPUT SECllON 
2010 PRlNT "The total cost of the therapy is $";TC 
2020 PRINT "The cost per day is $";CPD 
2030 PRINT "The cost per dose is $";CPDS 
2040 PRINT "The cost of the latx:>ratory tests is $";CL 
2050 PRINT "The cost of the material per dose is $";CS 
2052 PRlNT "The cost of the material per day is $";TCS 
2054 PRINT "The cost of the material per therapy is $" ;TTCS 
2060 PRINT "The cost of the personnel per dose is $";CP 
2062 PRINT "The cost of the personnel per day is $";TCP 
2064 PRINT "The cost of the personnel per therapy is $";TTCP 
2070 PRINT "The percentage of the personneVtherapy is";WTCP 
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